Adaptive Biotechnologies (ADPT) Debt to Equity (2022 - 2025)
Historic Debt to Equity for Adaptive Biotechnologies (ADPT) over the last 4 years, with Q3 2025 value amounting to $0.64.
- Adaptive Biotechnologies' Debt to Equity rose 874.82% to $0.64 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.64, marking a year-over-year increase of 874.82%. This contributed to the annual value of $0.66 for FY2024, which is 5518.83% up from last year.
- Per Adaptive Biotechnologies' latest filing, its Debt to Equity stood at $0.64 for Q3 2025, which was up 874.82% from $0.74 recorded in Q2 2025.
- Over the past 5 years, Adaptive Biotechnologies' Debt to Equity peaked at $0.74 during Q2 2025, and registered a low of $0.27 during Q4 2022.
- In the last 4 years, Adaptive Biotechnologies' Debt to Equity had a median value of $0.57 in 2024 and averaged $0.54.
- Its Debt to Equity has fluctuated over the past 5 years, first soared by 6510.65% in 2024, then skyrocketed by 874.82% in 2025.
- Adaptive Biotechnologies' Debt to Equity (Quarter) stood at $0.27 in 2022, then skyrocketed by 56.87% to $0.42 in 2023, then skyrocketed by 55.19% to $0.66 in 2024, then dropped by 1.92% to $0.64 in 2025.
- Its Debt to Equity stands at $0.64 for Q3 2025, versus $0.74 for Q2 2025 and $0.7 for Q1 2025.